Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
August 25, 2010
Despite PGx Leads, Avastin Access Debate Not Focused on Personalized Medicine Strategies
Despite pleas of breast cancer advocates to maintain access to Avastin using gene markers to identify those most likely to benefit, there is little evidence to suggest that the drug company or regulatory experts are considering this strategy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
February 23, 2011 / Pharmacogenomics Reporter - NCI's Proposed IP Policy May Hinder Personalized Medicine, Stakeholders Say
August 25, 2010 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter - FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter